Alzinova AB
- Biotech or pharma, therapeutic R&D
ALZ-101 is an amyloid-beta oligomer specific vaccine in Phase 1b, and ALZ-201 is an amyloid-beta oligomer specific mAb in preclinical phase. Efficacy proven in animal and cell-based models using patient brain material.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}